Oncovir

Activating Innate & Adaptive Immunity

Oncovir, Inc is a pharmaceutical corporation dedicated to the development of nucleic-acid-based clinical therapies for cancer, infectious, immune, and degenerative disorders.

We promote Hiltonol® (poly-ICLC) as an experimental viral mimic and broad activator of innate and adaptive immunity. While initially developed as an interferon inducer, Hiltonol® has much broader biological effects in humans, including specific antiviral, immune activating, vaccine adjuvant, and antitumor actions. 

LATEST NEWS
PICLC in PORTER Immunotherapy Clinical Trial for Prostate Cancer
 
Oncovir will collaborate in a metastatic prostate cancer study with the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute. This study is designed to evaluate multiple clinical hypotheses and mechanistically-defined combinations to evaluate the safety and efficacy of immunotherapy combinations in participants with mCRPC who have received prior secondary androgen receptor signaling inhibitor therapy (eg, abiraterone, enzalutamide, apalutamide).

© 2019 by Oncovir, Inc.    Terms of Use

  • Twitter